Hemostasis: Platelet Aggregation, Coagulation, and Fibrinolysis

Core Idea

Hemostasis prevents bleeding through three coordinated steps: vascular constriction, platelet plug formation, and coagulation cascade activation. The intrinsic, extrinsic, and common pathways converge to generate thrombin, which converts fibrinogen to fibrin. Fibrinolysis by plasmin then dissolves the clot once healing is complete. Balance between clotting and dissolution maintains vascular integrity without pathological thrombosis.

How It's Best Learned

Study the three pathways separately, then map their convergence points. Use case studies of bleeding disorders (hemophilia, von Willebrand disease, thrombocytopenia) to understand how defects in each phase lead to different clinical presentations.

Common Misconceptions

Hemostasis is not just clot formation—it's a dynamic balance between clotting and dissolution. The intrinsic and extrinsic pathways interact through tissue factor, not in isolation.

Explainer

You already know from your study of blood vessels that the vascular wall is the first barrier between circulating blood and the outside world. When that barrier is breached, the body needs to stop bleeding quickly but also precisely — a clot that is too small fails to seal the wound, while one that is too large could occlude the vessel and cause a stroke or heart attack. Hemostasis is the system that achieves this balance through three overlapping phases, each faster and more powerful than the last.

Primary hemostasis begins within seconds. Vascular smooth muscle contracts reflexively (vasospasm), narrowing the injured vessel to reduce blood flow. Simultaneously, exposed subendothelial collagen and von Willebrand factor (vWF) act as molecular anchors, capturing circulating platelets. You know from your cell signaling work that surface receptors trigger intracellular cascades: platelet binding to vWF activates GPIb receptors, which signals the platelet to change shape, degranulate (releasing ADP and thromboxane A₂), and recruit more platelets via GPIIb/IIIa fibrinogen crosslinks. The result is a soft, unstable platelet plug — adequate for minor injuries but insufficient alone for larger vessel tears.

Secondary hemostasis — the coagulation cascade — reinforces the plug with a fibrin mesh. You learned that the cascade runs through two initiation routes. The extrinsic pathway is faster: tissue factor (TF), exposed on damaged subendothelial cells, binds circulating Factor VII to form a TF-VIIa complex that rapidly activates Factors X and IX. The intrinsic pathway begins when Factor XII contacts exposed collagen surfaces, activating XI → IX → X. Both pathways converge on the common pathway: Factor X (with Factor V as cofactor) converts prothrombin to thrombin, the central enzyme of clotting. Thrombin then cleaves soluble fibrinogen into fibrin monomers that spontaneously polymerize, and activates Factor XIII to crosslink the fibrin strands into a rigid, covalently stabilized mesh. In clinical practice, the extrinsic pathway is assessed by PT (prothrombin time) and the intrinsic by aPTT (activated partial thromboplastin time).

Fibrinolysis dissolves the clot once tissue repair is underway. Endothelial cells release tissue plasminogen activator (tPA), which converts plasminogen (embedded in the clot) to plasmin. Plasmin cleaves fibrin into D-dimers and other degradation products, gradually dissolving the mesh. The balance between clotting factors and their inhibitors (antithrombin III, protein C, protein S, TFPI) ensures that clot formation stays local. When this balance fails — through factor deficiency (hemophilia A = Factor VIII, hemophilia B = Factor IX) or excess (Factor V Leiden mutation making Factor V resistant to protein C) — the result is either uncontrolled bleeding or pathological thrombosis.